March 28, 2013
Michigan State University (MSU) researchers report the need for stronger protections -- vaccination for hepatitis B and additional blood transfusion safeguards -- to prevent hepatitis coinfection for HIV-infected people. Based on a review of all registered Michigan HIV cases, lead researcher Zahid Butt stated that approximately four percent of HIV-infected people were coinfected with hepatitis. Butt asserted that the prevalence of HIV and hepatitis B and C coinfection in Michigan was higher than expected, given the existing blood screening protocols.
According to CDC, HIV infection "more than triples" the risk of death from liver disease and liver failure for people with hepatitis C. Hepatitis B and C attack the liver; untreated hepatitis infections can be fatal.
In contrast to earlier studies that indicated African-American males have higher coinfection rates, the MSU study found males who marked their race as "other" had the highest coinfection rates. Butt theorized the higher rates among this group were due to insufficient safeguards during blood transfusions and lack of hepatitis B vaccination. He suggested the high coinfection cohort might have originated in countries that do not require childhood immunization for hepatitis B. Distrust of the healthcare system could also discourage people from hepatitis B immunization.
To prevent future hepatitis infections among HIV-infected persons, Butt recommended "proper screening" of blood products used for transfusions and hepatitis vaccination for all HIV-infected individuals.
The full report, "Hepatitis B and C Co-infection in HIV/AIDS Population in the State of Michigan," was published online March 12, 2013, in the journal Epidemiology and Infection.
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|What Would an HIV Cure Mean for You?|
|Condomless Anal Sex Rising in U.S. MSM With or Without HIV Infection|
|If We Act to Remove Structural, Behavioral and Social Barriers, We Can End the HIV Epidemic With the Medicines We Already Have|
|This Week in HIV Research: Immune System Differences Could Produce bNAbs; New HIV Infections Are No Longer Falling; and Zoledronic Acid May Prevent Bone Loss|
|What's the Next Game-Changer in HIV Treatment?|